CompletedPhase 2

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

United States16 participantsStarted 2015-01

Plain-language summary

The goal of the study is to assess the efficacy and safety of mifepristone 300 or 900-mg once-daily dosing by mouth for 4 weeks in patients with central serous chorioretinopathy.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Diagnosis of central serous chorioretinopathy (CSC) with symptoms 6 weeks or prior documented episodes of sub-retinal fluid; patients who have had previous treatment for CSC may be included
. Presence of sub-retinal fluid as documented on optical coherence tomography (OCT) in the central foveal sub-field
. Age 18 or over
. Willing and able to comply with clinic visits and study-related procedures
. Ability to give written informed consent

Exclusion criteria

. Age less than 18
. Persons with impaired decision-making ability.
. Women who are known to be breast-feeding, pregnant or are actively trying to conceive.
. Additional eye disease affecting the macula, posterior retina, or ocular media that would limit or prevent the acquisition of OCT and angiographic images.
. At screening, serum potassium \< LLN, BUN \> 1.5 ULN, serum creatinine \>1.5 ULN, AST \> 1.5 ULN, ALT \>1.5 ULN, bilirubin \> 1.5 ULN, alkaline phosphatase \> 1.5 ULN, serum albumin \>1.5 ULN or \<LLN.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Resolution of Sub-retinal Fluid

Timeframe: 4 weeks after treatment

Trial details

NCT IDNCT02354170

SponsorRoger Goldberg, M.D., MBA

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-04-27

View on ClinicalTrials.gov More Central Serous Chorioretinopathy trials